The application of novel field measurement and field evaluation protocols for assessing health care workers’ exposure risk to antineoplastic drugs

References

• ASSTSAS. 2008. Prevention guide: safe handling of hazardous drugs. Montreal. http://www.irsst.qc.ca/media/documents/pubirsst/cg-002.pdf (accessed September 19, 2019).
   Google Scholar
• BCCA. 2018. Facts and figures. Vancouver. http://www.bccancer.bc.ca/statistics-and-reports-site/Documents/HSDA_incidence_2018_2033.pdf.
   Google Scholar
• Berruyer M, Tanguay C, Caron NJ, Lefebvre M, Bussières JF. 2015. Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian Hospitals: a 2013 follow-up study. J Occup Environ Hyg. 12(2):87–94. doi:10.1080/15459624.2014.949725
   PubMed Web of Science ®Google Scholar
• Böhlandt A, Sverdel Y, Schierl R. 2017. Antineoplastic drug residues inside homes of chemotherapy patients. Int J Hyg Environ Health. 220(4):757–765. doi:10.1016/j.ijheh.2017.03.005
   PubMed Web of Science ®Google Scholar
• Bussières JF, Tanguay C, Touzin K, Langlois É, Lefebvre M. 2012. Environmental contamination with hazardous drugs in Quebec hospitals. Can J Hosp Pharm. 65(6):428–435. doi:10.4212/cjhp.v65i6.1190
   PubMedGoogle Scholar
• Chu WC, Hon C-Y, Danyluk Q, Chua PPS, Astrakianakis G. 2012. Pilot assessment of the antineoplastic drug contamination levels in British Columbian hospitals pre- and post-cleaning. J Oncol Pharm Pract. 18(1):46–51. doi:10.1177/1078155211402106
   PubMedGoogle Scholar
• Colombo M, Jeronimo M, Astrakianakis G, Apte C, Hon C-Y. 2017. Wipe sampling method and evaluation of environmental variables for assessing surface contamination of 10 antineoplastic drugs by liquid chromatography/tandem mass spectrometry. Ann Work Expo Health. 61(8):1003–1014. doi:10.1093/annweh/wxx070
   PubMed Web of Science ®Google Scholar
• Connor TH, DeBord DG, Pretty JR, Oliver MS, Roth TS, Lees PS, Krieg EF, Jr., Rogers B, Escalante CP, Toennis CA, et al. 2010. Evaluation of antineoplastic drug exposure of health care workers at three university-based US cancer centers. J Occup Environ Med. 52(10):1019–1027. doi:10.1097/JOM.0b013e3181f72b63
   PubMed Web of Science ®Google Scholar
• Connor TH, McDiarmid MA. 2006. Preventing occupational exposures to antineoplastic drugs in health care settings. CA Cancer J Clin. 56(6):354–365. doi:10.3322/canjclin.56.6.354
   PubMed Web of Science ®Google Scholar
• Connor TH, Zock MD, Snow AH. 2016. Surface wipe sampling for antineoplastic (chemotherapy) and other hazardous drug residue in healthcare settings: methodology and recommendations. J Occup Environ Hyg. 13(9):658–667. doi:10.1080/15459624.2016.1165912
   PubMed Web of Science ®Google Scholar
• Dranitsaris G, Johnston M, Poirier S, Schueller T, Milliken D, Green E, Zanke B. 2005. Are health care providers who work with cancer drugs at an increased risk for toxic events? A systematic review and meta-analysis of the literature. J Oncol Pharm Pract. 11(2):69–78. doi:10.1191/1078155205jp155oa
   PubMedGoogle Scholar
• Fransman W, Roeleveld N, Peelen S, De Kort W, Kromhout H, Heederik D. 2007. Nurses with dermal exposure to antineoplastic drugs: reproductive outcomes. Epidemiology. 18(1):112–119. doi:10.1097/01.ede.0000246827.44093.c1
   PubMed Web of Science ®Google Scholar
• Gabay M. 2014. USP <800>: handling hazardous drugs. Hosp Pharm. 49(9):811–812.
   PubMedGoogle Scholar
• Gunnarsdottir HK, Aspelund T, Karlsson T, Rafnsson VV. 1997. Occupational risk factors for breast cancer among nurses. Int J Occup Environ Health. 3(4):254–258. doi:10.1179/oeh.1997.3.4.254
   PubMedGoogle Scholar
• Hall AL, Demers PA, Astrakianakis G, Ge C, Peters CE. 2017. Estimating national-level exposure to antineoplastic agents in the workplace: CAREX Canada findings and future research needs. Ann Work Expo Health. 61(6):656–658. doi:10.1093/annweh/wxx042
   PubMed Web of Science ®Google Scholar
• Hedmer M, Tinnerberg H, Axmon A, Jönsson B. 2008. Environmental and biological monitoring of antineoplastic drugs in four workplaces in a Swedish hospital. Int Arch Occup Environ Health. 81(7):899–911. doi:10.1007/s00420-007-0284-y
   PubMed Web of Science ®Google Scholar
• Hedmer M, Wohlfart G. 2012. Hygienic guidance values for wipe sampling of antineoplastic drugs in Swedish hospitals. J Environ Monit. 14(7):1968–1975. doi:10.1039/c2em10704j
   PubMedGoogle Scholar
• Hon CY, Teschke K, Chu W, Demers P, Venners S. 2013. Antineoplastic drug contamination of surfaces throughout the hospital medication system in Canadian hospitals. J Occup Environ Hyg. 10(7):374–383. doi:10.1080/15459624.2013.789743
   PubMed Web of Science ®Google Scholar
• Hon CY, Teschke K, Chua P, Venners S, Nakashima L. 2011. Occupational exposure to antineoplastic drugs: identification of job categories potentially exposed throughout the hospital medication system. Saf Health Work. 2(3):273–281. doi:10.5491/SHAW.2011.2.3.273
   PubMedGoogle Scholar
• Hon CY, Teschke K, Demers PA, Venners S. 2014. Antineoplastic drug contamination on the hands of employees working troughout the hospital medication system. Ann Occup Hyg. 58(6):761–770.
   PubMedGoogle Scholar
• Hon CY, Teschke K, Shen H, Demers PA, Venners S. 2015. Antineoplastic drug contamination in the urine of Canadian healthcare workers. Int Arch Occup Environ Health. 88(7):933–941. doi:10.1007/s00420-015-1026-1
   PubMed Web of Science ®Google Scholar
• Jeronimo M, Colombo M, Astrakianakis G, Hon CY. 2015. A surface wipe sampling and LC-MS/MS method for the simultaneous detection of six antineoplastic drugs commonly handled by healthcare workers. Anal Bioanal Chem. 407(23):7083–7092. doi:10.1007/s00216-015-8868-y
   PubMed Web of Science ®Google Scholar
• Kopp B, Schierl R, Nowak D. 2013. Evaluation of working practices and surface contamination with antineoplastic drugs in outpatient oncology health care settings. Int Arch Occup Environ Health. 86(1):47–55. doi:10.1007/s00420-012-0742-z
   PubMed Web of Science ®Google Scholar
• Lawson CC, Rocheleau CM, Whelan EA, Lividoti Hibert EN, Grajewski B, Spiegelman D, Rich-Edwards JW. 2012. Occupational exposures among nurses and risk of spontaneous abortion. Am J Obstet Gynecol. [Internet]. 206(4):327.e1–e8. doi:10.1016/j.ajog.2011.12.030
   Web of Science ®Google Scholar
• McDiarmid MA, Oliver MS, Roth TS, Rogers B, Escalante C. 2010. Chromosome 5 and 7 abnormalities in oncology personnel handling anticancer drugs. J Occup Environ Med. 52(10):1028–1034. doi:10.1097/JOM.0b013e3181f73ae6
   PubMed Web of Science ®Google Scholar
• McDiarmid MA, Rogers B, Oliver MS. 2014. Chromosomal effects of non-alkylating drug exposure in oncology personnel. Environ Mol Mutagen. 55(4):369–374. doi:10.1002/em.21852
   PubMed Web of Science ®Google Scholar
• NIOSH. 2004. Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings. Cincinati. https://www.cdc.gov/niosh/docs/2004-165/ (accessed September 19, 2019).
   Google Scholar
• Poupeau C, Tanguay C, Caron NJ, Bussières JF. 2018. Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals. J Oncol Pharm Pract. 24(1):9–17. doi:10.1177/1078155216676632
   PubMed Web of Science ®Google Scholar
• Ratner PA, Spinelli JJ, Beking K, Lorenzi M, Chow Y, Teschke K, Le ND, Gallagher RP, Dimich-Ward H. 2010. Cancer incidence and adverse pregnancy outcome in registered nurses potentially exposed to antineoplastic drugs. BMC Nurs. 9:15. doi:10.1186/1472-6955-9-15
   PubMedGoogle Scholar
• Saurel-Cubizolles MJ, Job-Spira N, Estryn-Behar M. 1993. Ectopic pregnancy and occupational exposure to antineoplastic drugs. Lancet. 341(8854):1169–1171. doi:10.1016/0140-6736(93)91000-C
   PubMed Web of Science ®Google Scholar
• Schierl R, Böhlandt A, Nowak D. 2009. Guidance values for surface monitoring of antineoplastic drugs in German pharmacies. Ann Occup Hyg. 53(7):703–711. doi:10.1093/annhyg/mep050
   PubMed Web of Science ®Google Scholar
• Siderov J, Kirsa S, McLauchlan R. 2009. Surface contamination of cytotoxic chemotherapy preparation areas in Australian Hospital Pharmacy Departments. J Pharm Pract Res. 39(2):117–121.
   Google Scholar
• Skov T, Maarup B, Olsen J, Rørth M, Winthereik H, Lynge E. 1992. Leukaemia and reproductive outcome among nurses handling antineoplastic drugs. Br J Ind Med. 49(12):855–861. doi:10.1136/oem.49.12.855
   PubMedGoogle Scholar
• Sugiura SI, Asano M, Kinoshita K, Tanimura M, Nabeshima T. 2011. Risks to health professionals from hazardous drugs in Japan: A pilot study of environmental and biological monitoring of occupational exposure to cyclophosphamide. J Oncol Pharm Pract. 17(1):14–19. doi:10.1177/1078155209358632
   PubMedGoogle Scholar
• Turci R, Sottani C, Spagnoli G, Minoia C. 2003. Biological and environmental monitoring of hospital personnel exposed to antineoplastic agents: a review of analytical methods. J Chromatogr B Anal Technol Biomed Life Sci. 789(2):169–209. doi:10.1016/S1570-0232(03)00100-4
   PubMed Web of Science ®Google Scholar
• USP. 2018. USP general chepter <800> hazardous drugs: handling in health care settings. USP General Chapter <800>; 20p. https://go.usp.org/e/323321/34-323321-72807-USP-GC-800-pdf/37vvsb/248181929?h=PL4unpZQX3kzbdGJNs-qvfRwpXMZPkEl2DgBuhPlnco.
   Google Scholar